earnings
confidence high
sentiment positive
materiality 0.80
BeOne Medicines Q2 2025 revenues jump 42% to $1.3B; GAAP EPS $0.84
BeOne Medicines Ltd.
2025-Q2 EPS reported
$0.07
revenue$2,432,579,000
- Total revenues $1.315B vs $929M YoY (+42%); BRUKINSA revenues up 49% to $950M.
- GAAP net income $94.3M ($0.84 diluted EPS/ADS) vs loss of $120.4M a year ago.
- Non-GAAP diluted EPS $2.25, adjusted income from operations $274.9M (up 467% YoY).
- Free cash flow positive $219.8M vs negative $205.5M in Q2 2024.
- Company expects 20+ R&D milestones in next 18 months across hematology and solid tumors.
item 2.02item 9.01